Gilead Sciences (GILD) Misses Q3 EPS by 11c; Reiterates Outlook
Gilead Sciences (NASDAQ: GILD) reported Q3 EPS of $2.75, $0.11 worse than the analyst estimate of $2.86. Revenue for the quarter came in at $7.4 billion versus the consensus estimate of $7.45 billion.Gilead Sciences reaffirmed FY2016 guidance.
Full Year 2016 Guidance Reiterated
Gilead reiterates its full year 2016 guidance, as revised on July 25, 2016:
| (In millions, except percentages and per share amounts) | Updated July 25, 2016 Reiterated November 1, 2016 | |
| Net Product Sales | $29,500 - $30,500 | |
| Non-GAAP* | ||
| Product Gross Margin | 88% - 90% | |
| R&D Expenses | $3,600 - $3,800 | |
| SG&A Expenses | $3,100 - $3,300 | |
| Effective Tax Rate | 18.0% - 20.0% | |
| Diluted EPS Impact of Acquisition-related, Up-front Collaboration, Stock-based Compensation and Other Expenses | $1.47 - $1.53 |
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.